Kymera Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $459.6M | $48.0M |
| FY2022 | — | $490.2M | $68.4M |
| FY2023 | — | $395.0M | $110.0M |
| FY2024 | — | $835.6M | $120.3M |
| FY2025 | — | $1.58B | $357.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $459.6M | $48.0M |
| FY2022 | — | $490.2M | $68.4M |
| FY2023 | — | $395.0M | $110.0M |
| FY2024 | — | $835.6M | $120.3M |
| FY2025 | — | $1.58B | $357.0M |